
GOSS Stock Forecast & Price Target
GOSS Analyst Ratings
Bulls say
Gossamer Bio Inc. is supported by overwhelmingly positive key opinion leader (KOL) sentiment, particularly regarding the anticipated success of PROSERA in treating pulmonary arterial hypertension (PAH), with projected treatment effects ranging between 25 to 30 meters in the 6-minute walk distance (6MWD). The phase 2 TORREY trial data displayed consistent benefits across various endpoints, demonstrating reductions in pulmonary vascular resistance (PVR) and pro-BNP levels, alongside a notable increase in 6MWD, suggesting strong therapeutic potential for the company's product pipeline. Engagement from investors at recent conferences reflects heightened interest in Gossamer Bio, driven by encouraging data and optimistic expert commentary.
Bears say
Gossamer Bio Inc. faces a negative outlook as the market continues to misprice the odds of success for its leading candidate, Seralutinib, despite a recent increase in stock value. This mispricing indicates potential overvaluation, raising concerns about the sustainability of the stock’s upward momentum. Additionally, the reliance on a clinical-stage pipeline without fully realized or commercialized products poses inherent risks that could negatively affect the company's financial stability.
This aggregate rating is based on analysts' research of Gossamer Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
GOSS Analyst Forecast & Price Prediction
Start investing in GOSS
Order type
Buy in
Order amount
Est. shares
0 shares